Cagrillintide

Cagrilintide is an injectable peptide analog administered once a week that simultaneously activates glucagon-like peptide-1 (GLP-1), glucose-dependent insulinotropic polypeptide (GIP), and glucagon receptors. Its mechanism as a triple agonist places it among the most advanced compounds in metabolic research currently undergoing active preclinical and clinical studies globally.

Initially developed by Novo Nordisk with the research code AM833, cagrilintide was granted its International Nonproprietary Name (INN) after being designated as a clinical candidate. The compound includes a C18 fatty acid acylation linker that is connected to a modified glucagon-family peptide backbone, which provides resistance to dipeptidyl peptidase-4 (DPP-4) degradation and prolongs the plasma half-life to about 7 days in human subjects. This enhanced pharmacokinetic profile renders it especially useful for creating stable, once-weekly exposure protocols in research models.